Dr. Agarwal’s Health Care Limited IPO
The Company offer a full spectrum of eye care services, including surgical, non-surgical, and retail offerings:
Surgical Services:-
i. Cataract Surgeries: Advanced options like small incision cataract surgery, phacoemulsification, robotic cataract surgery, and glued intraocular lens treatments.
ii. Refractive Surgeries: Procedures like LASIK, SMILE, implantable collamer lens treatment, and photo-refractive keratectomy to reduce or eliminate dependence on glasses and contact lenses.
iii. Other Surgeries: Specialized treatments such as retinal surgeries, corneal transplants, pinhole pupilloplasty, oculoplasty, and glaucoma surgeries.
Consultations and Non-Surgical Treatments:-
i. Doctor consultations and diagnostic services for eye disorders.
ii. Non-surgical treatments like retinal laser therapy and dry eye treatments.
Retail Products:-
i. Sale of opticals, contact lenses, and accessories, including glasses, lenses, and frames.
ii. Sale of eye care pharmaceutical products prescribed by in-house doctors.
Market Leadership and Reach
According to the CRISIL MI&A Report:
i. They captured a 25% market share of India’s total eye care service chain market in FY 2024.
ii. As of September 30, 2024, they operated the highest number of eye care facilities in India among listed and unlisted peers, with a network of 209 facilities.
Continuous Growth and Innovation
With a long-standing operational history, they remain committed to meeting patients’ eye care needs comprehensively. Leveraging advanced technology, specialized care, and retail offerings, they continue to lead the Indian eye care market, strengthening our position as a trusted provider of holistic eye care solutions.
Objects of the Dr. Agarwal’s Health Care Limited IPO:
Dr. Agarwal’s Health Care Limited IPO Details:
Open Date: | Jan 29 2025 |
Close Date: | Jan 31 2025 |
Total Shares: | 7,53,04,970 |
Face Value: | ₹ 1 Per Equity Share |
Issue Size: | 3,027.26 Cr. |
Lot Size: | 35 Shares |
Issue Price: | ₹ 382 - 402 Per Equity Share |
Listing At: | NSE,BSE |
Listing Date: | Feb 05 2025 |
Promoters And Management:
Financials of Dr. Agarwal’s Health Care Limited IPO:
Particulars | Sep 30, 2024 | March 31, 2024 | March 31, 2023 | March 31, 2022 |
---|---|---|---|---|
Revenue from Operations | 820.06 | 1332.15 | 1017.98 | 696.07 |
Growth in Revenue | 30.86% | 46.25% | ||
EBITDA | 228.47 | 406.55 | 283.86 | 199.82 |
EBITDA Margins | 27.27% | 29.54% | 27.52% | 27.99% |
PAT | 39.56 | 95.05 | 103.23 | 43.16 |
PAT Margins | 4.72% | 6.91% | 10.01% | 6.05% |
ROCE | 14.61% | 15.18% | 15.02% | |
CFOA | 201.97 | 345.95 | 233.10 | 164.32 |
Operating Cash Flow to EBITDA | 88.40% | 85.10% | 82.12% | 82.24% |
Comparison With Peers:
Companies | Revenue | EBITDA Margins | PAT Margins | D/E Ratio | MCap | P/E |
Dr. Agarwal's Health Care (FY 2024) | 1332.15 Cr. | 29.54% | 6.91% | 0.24 | 12,698 Cr. | 133 |
Apollo Hospitals Enterprise Limited (TTM) | 20,469 Cr. | 13% | 5.98% | 0.98 | 96,522 Cr. | 81.60 |
Max Healthcare Institute (TTM) | 6,008 Cr. | 27% | 17.62% | 0.20 | 99,517 Cr. | 94 |
Fortis Healthcare (TTM) | 7,313 Cr. | 20% | 9.62% | 0.15 | 44,743 Cr. | 65 |
Global Health (TTM) | 3,463 Cr. | 23% | 14.09% | 0.22 | 27,325 Cr. | 56 |
Narayana Hrudayalaya (TTM) | 5,224 Cr. | 23% | 14.91% | 0.53 | 26,364 Cr. | 33.9 |
Krishna Institute of Medical Sciences (TTM) | 2,705 Cr. | 26% | 13.45% | 0.89 | 23,626 Cr. | 71.30 |
Aster DM Healthcare (TTM) | 4,017 Cr. | 17% | 136% | 0.56 | 24,214 Cr. | 87.90 |
Rainbow Children's Medicare (TTM) | 1,425 Cr. | 33% | 16.28% | 0.57 | 14,042 Cr. | 60.60 |
Recommendation on Dr. Agarwal’s Health Care Limited IPO:
Lead Manager of Dr. Agarwal’s Health Care Limited IPO:
Registrar of Dr. Agarwal’s Health Care Limited IPO:
Company Address:
Discussion on Dr. Agarwal’s Health Care Limited IPO:
Leave a Reply
You must be logged in to post a comment.